<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02079506</url>
  </required_header>
  <id_info>
    <org_study_id>DP-CTR208-I-01</org_study_id>
    <nct_id>NCT02079506</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin</brief_title>
  <official_title>An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Candesartan 32 mg and Rosuvastatin 20 mg in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alvogen Korea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alvogen Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare pharmacokinetics after single oral administration
      of candesartan and rosuvastatin each separately versus coadministration of candesartan and
      rosuvastatin in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss of candesartan</measure>
    <time_frame>22 points</time_frame>
    <description>0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of candesartan</measure>
    <time_frame>22 points</time_frame>
    <description>0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss of rosuvastatin</measure>
    <time_frame>28 points</time_frame>
    <description>0(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of rosuvastatin</measure>
    <time_frame>28 points</time_frame>
    <description>0(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax,ss of candesartan</measure>
    <time_frame>22 points</time_frame>
    <description>0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F of candesartan</measure>
    <time_frame>22 points</time_frame>
    <description>0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss of candesartan</measure>
    <time_frame>22 points</time_frame>
    <description>0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss of rosuvastatin</measure>
    <time_frame>28 points</time_frame>
    <description>0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F of rosuvastatin</measure>
    <time_frame>28 points</time_frame>
    <description>0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss of rosuvastatin</measure>
    <time_frame>28 points</time_frame>
    <description>0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers af aged between 20 years to 45 years

          -  Have a weight above 55kg and Ideal body weight (IBW) between -20% and +20% inclusive

          -  Eligible subjects with acceptable medical history and physical examination

        Exclusion Criteria:

        - Have a known hypersensitivity or history of clinically significant hypersensitivity to
        drugs including the same class drugs with candesartan or rosuvastatin, or other drugs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JangHee Hong, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Jung-gu</city>
        <state>Daejeon</state>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

